ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 245 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.36 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,580,625 | +61.6% | 171,815 | +85.7% | 0.00% | +100.0% |
| Q2 2023 | $2,215,782 | +82.0% | 92,517 | +43.0% | 0.00% | 0.0% |
| Q1 2023 | $1,217,579 | +40.4% | 64,696 | +18.7% | 0.00% | – |
| Q4 2022 | $867,481 | -9.6% | 54,490 | -7.2% | 0.00% | -100.0% |
| Q3 2022 | $960,000 | +7.7% | 58,702 | -7.2% | 0.00% | – |
| Q2 2022 | $891,000 | -48.3% | 63,250 | -11.1% | 0.00% | -100.0% |
| Q1 2022 | $1,724,000 | -4.9% | 71,186 | -8.3% | 0.00% | 0.0% |
| Q4 2021 | $1,812,000 | +6.4% | 77,627 | -24.3% | 0.00% | 0.0% |
| Q3 2021 | $1,703,000 | -33.4% | 102,503 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $2,558,000 | -2.2% | 104,893 | +3.5% | 0.00% | -50.0% |
| Q1 2021 | $2,616,000 | +123.4% | 101,380 | +363.0% | 0.00% | +100.0% |
| Q4 2020 | $1,171,000 | +52.3% | 21,897 | +17.4% | 0.00% | 0.0% |
| Q3 2020 | $769,000 | -0.6% | 18,647 | +16.8% | 0.00% | 0.0% |
| Q2 2020 | $774,000 | +15.7% | 15,964 | +0.8% | 0.00% | 0.0% |
| Q1 2020 | $669,000 | +15.5% | 15,844 | +17.1% | 0.00% | 0.0% |
| Q4 2019 | $579,000 | +51.2% | 13,529 | +27.2% | 0.00% | – |
| Q3 2019 | $383,000 | +128.0% | 10,634 | +2.7% | 0.00% | – |
| Q4 2018 | $168,000 | +1766.7% | 10,359 | +1573.5% | 0.00% | – |
| Q2 2018 | $9,000 | -25.0% | 619 | +16.4% | 0.00% | – |
| Q1 2018 | $12,000 | +20.0% | 532 | +67.3% | 0.00% | – |
| Q4 2017 | $10,000 | -41.2% | 318 | -31.0% | 0.00% | – |
| Q3 2017 | $17,000 | -72.1% | 461 | -78.9% | 0.00% | – |
| Q2 2017 | $61,000 | -46.0% | 2,190 | -33.6% | 0.00% | – |
| Q1 2017 | $113,000 | +46.8% | 3,296 | +23.0% | 0.00% | – |
| Q4 2016 | $77,000 | -11.5% | 2,679 | -2.2% | 0.00% | – |
| Q3 2016 | $87,000 | -28.1% | 2,740 | -26.6% | 0.00% | – |
| Q2 2016 | $121,000 | +33.0% | 3,734 | +14.2% | 0.00% | – |
| Q1 2016 | $91,000 | +24.7% | 3,271 | +58.9% | 0.00% | – |
| Q4 2015 | $73,000 | +9.0% | 2,059 | +2.2% | 0.00% | – |
| Q3 2015 | $67,000 | +6600.0% | 2,015 | +5202.6% | 0.00% | – |
| Q3 2014 | $1,000 | 0.0% | 38 | 0.0% | 0.00% | – |
| Q2 2014 | $1,000 | 0.0% | 38 | 0.0% | 0.00% | – |
| Q1 2014 | $1,000 | – | 38 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |